Gene Therapy for Neurological Disorders

Built with the field's thought-leaders from the likes of Pfizer, Biogen, Voyager and Novartis, GTxN is the industry's first and only meeting dedicated to solving your translational drug development challenges enabling you to accelerate the development of your neurological gene therapy candidate.

- Review recent gene therapy clinical successes and failures targeting neurological disorders to identify improvement areas and opportunities to guide your future research
- Discover the latest advances in administration routes and vector engineering to improve delivery success
- Address immunogenicity and the dosage challenges seen with gene therapies to identify the optimal therapeutic window

Join 60+ of your peers at this definitive conference over 3 days, 2 interactive workshops, 6+ hours of dedicated networking time and 18 expert industry speakers.

Others Details

URL: Brochure: https://go.evvnt.com/503662-3?pid=6581 Speakers: Boris Gorovits, Senior Director, Pfizer, Carl Morris, Chief Scientific Officer, Solid Biosciences, Greg LaRosa, Senior Vice President and Chief Scientific Officer, Rare Disease Research Unit, Pfizer, Joyce Lo, Scientist II, Biogen, Mark Milton, Global Head, Pharmacokinetic Sciences Ophthalmology Therapeutic Area and Department Lead for Gene Therapies, Novartis and more. Time: 09:00 - 17:00